Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Cash: 2021-2025

Historic Change in Cash for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $17.6 million.

  • Prime Medicine's Change in Cash fell 72.05% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 162.95%. This contributed to the annual value of $141.5 million for FY2024, which is 196.87% up from last year.
  • Prime Medicine's Change in Cash amounted to $17.6 million in Q3 2025, which was up 145.76% from -$38.4 million recorded in Q2 2025.
  • Prime Medicine's 5-year Change in Cash high stood at $139.7 million for Q4 2022, and its period low was -$90.6 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Cash was -$12.9 million (2023), whereas its average is -$10.5 million.
  • As far as peak fluctuations go, Prime Medicine's Change in Cash soared by 6,691.46% in 2022, and later slumped by 272.28% in 2025.
  • Over the past 5 years, Prime Medicine's Change in Cash (Quarterly) stood at -$2.1 million in 2021, then skyrocketed by 6,691.46% to $139.7 million in 2022, then plummeted by 101.71% to -$2.4 million in 2023, then spiked by 2,804.36% to $64.5 million in 2024, then slumped by 72.05% to $17.6 million in 2025.
  • Its Change in Cash was $17.6 million in Q3 2025, compared to -$38.4 million in Q2 2025 and -$90.6 million in Q1 2025.